SPINRAZA becomes first available treatment for adults living with SMA

From 1 August 2022, adults (at least 19 years of age or older) with 5q Spinal Muscular Atrophy (SMA) and symptom onset prior to their 19^th birthday will be able to access SPINRAZA^® (nusinersen) on the Pharmaceutical Benefits Scheme (PBS), the first and only reimbursed treatment for this patient population in Australia.

(Excerpt from Biogen’s News Announcement).

Read the full post